Loading viewer...
earnings
Format: PDF earnings
Natera reported strong 2021 results with 1.57M tests processed and $625.5M revenue (+60% YoY), alongside landmark clinical achievements including the CIRCULATE-Japan study validating Signatera MRD for colorectal cancer and publication of the SMART 22q11.2 deletion trial. The company guided 2022 revenue of $770-790M, reflecting continued momentum in its non-invasive prenatal testing and oncology diagnostics businesses.
earnings
21 Pages
earnings
34 Pages
PHH Corporation
Carpenter Technology 2016 Earnings Call Q4 FY Results
earningsearnings
22 Pages
Carpenter Technology
The Hartford Q2 2023 Earnings Results & Financial Performance
earningsearnings
19 Pages
The Hartford Financial Services Group, Inc.
Sibanye Stillwater H1 2023 Operating & Financial Results Presentation
earningsearnings
68 Pages
Sibanye Stillwater Limited
Kuehne + Nagel 2016 Full-Year Results Analyst Conference
earningsearnings
28 Pages
Kuehne + Nagel International